serious rerating ahead, page-28

we're currently witnessing some price stability after a sharp rise last week. This is what is needed for further rises.

With OvPlex hitting the UK market, I feel this is just the beginning for this company. We await further news on discussions for further distribution in other countries around the world with the US being the no.1 targeted market having 8 million tests for Ovarian cancer per year.

Nick mentioned the company hoped to capture 30% of the US market within 5 years (he comes across conservative). That would be 2.4 million tests to HTX and some $168m in profit at the going $70 per test rate.

If they only captured 30% of the UK market, net profit would be close to todays market cap. It's as if the market isn't valueing the company on potential at all.

We could easily have a market cap of $50m today and the company would be nowhere near overpriced considering;

- entry into UK market
- discussions open with China, Korea, Singapore and India
- superior product and entry to more markets only a matter of time.
- South American countries approaching HTX, in demand

Note a $50m market cap would be a 150% return on the current price and there is so much more potential upside.

I can't hide my delight being invested in this company. I like to tread carefully in any industry but if OvPlex is to become the market leader in detecting a life threatening illness in women and potentially save lives, then the skies the limit.

Good luck all